Global Hydraulic Press Machine Market to Witness 4.8% CAGR during 2017 - 2023     |   Global Auto-Injectors Market to Witness 18.6% CAGR during 2017 – 2023     |    Global Ammonium Phosphate Market to Witness 3.6% CAGR During 2016 – 2022

Toll Free (US/Canada): 1-888-778-7886

INT'L: 1-347-960-6455

enquiry@psmarketresearch.com

P&S Market Research - A market research firm

Osteoporosis Drugs Market

P&S Market Research-Osteoporosis Drugs Market report

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022 – Industry Insights by Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Receptor Modulators, Rank Ligand Inhibitor, Calcitonin and Others)

Published: November 2016
Report Code: LS10177
Available Format: pdf
Pages: 94

The global osteoporosis drugs market was worth $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various drug classes, the rank ligand inhibitors segment is expected to witness the fastest growth, a CAGR of 4.3% during the forecast period.

Osteoporosis disease is the most common bone disease occurring due to reduced bone mineral density, thus increasing risk of fractures and fragile bones. It leads to abnormally porous bones such as sponge, which facilitates weakening of bones and painful fracture. Bone mineral density decreases naturally with age, and hence aging population face high risks of osteoporosis. The decline in bone strength is only visible after the bone gets fractured. Most of the spine, hip, shoulder and forearm fractures occur in aged people of 65 years and above. One of the major procedures to build stronger muscle and bones is exercising regularly during the teenage years, which in turn leads to a lower risk of osteoporosis disease. The increasing trend of inactive lifestyle and obesity leads to growing prevalence of osteoporosis disease.

 

GLOBAL OSTEOPOROSIS DRUG MARKET BY DRUG TYPE $M (2012–2022)

Some of the signs and symptoms of the osteoporosis are falling risk and fractures. Diagnostic tests of osteoporosis include X-Ray test and traditional radiography tests, which is further confirmed with the help of bone density test. Osteoporosis disease can be managed by nutrition emphasis, lifestyle management and medicines. According to National Osteoporosis Foundation, by 2025 osteoporosis would lead to approximately three million fractures.

Based on drug class, the global osteoporosis drugs market has been segmented as bisphosphonates, parathyroid hormone therapy, SERM’s, rank ligand inhibitor, calcitonin, and others. The bisphosphonates segment dominated the global market in 2015.

The global osteoporosis drugs market is growing due to growing geriatric population, increasing prevalence of osteoporosis in postmenopausal women and increasing healthcare expenditure. The increasing focus on research & development of new drugs for treatment of osteoporosis and increasing awareness of osteoporosis are also driving the growth of the global osteoporosis drugs market.

The restraints for the growth of the global osteoporosis drugs market include strict regulatory requirements for the approval of drugs and patent expiry of blockbuster drugs. The side-effects and complications associated with administration of osteoporosis drugs such as nausea, ulcer in stomach and irritable bowel syndrome are also hindering the growth of the global market.

Geographically, North America is expected to continue being the largest market for osteoporosis drugs globally, during 2016-2022. It is due to growing geriatric population and increasing awareness of osteoporosis. The European osteoporosis drugs market is growing at a significant rate mainly due to growing aging population, increasing prevalence of osteoporosis in postmenopausal women and increasing awareness of osteoporosis. However, the Asia-Pacific market of osteoporosis drugs is expected to witness the highest growth during the forecast period. This is due the growing geriatric population, increasing healthcare expenditure, large pool of patients, modifying lifestyle and increasing awareness of osteoporosis in the region.

Some of the key companies operating in the global osteoporosis drugs market include Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Novartis International AG, Merck & Co. Inc., and Amgen Inc.

Chapter 1. Research Scope and Methodology

1.1 Market Definition

1.2 Research Scope

1.2.1 Global osteoporosis drug market breakdown by drug type

1.2.2 Global osteoporosis drug market breakdown by geography

1.3 Research Methodology and Sources

Chapter 2. Executive Summary

2.1 Key Findings

2.2 Research Summary

Chapter 3. Market Outlook

3.1 Introduction

3.1.1 Causes

3.1.2 Signs and Symptoms

3.1.3 Diagnosis

3.1.4 Prevention and Treatment

3.2 Trends in the Global Osteoporosis Drug Market

3.2.1 Increasing awareness of osteoporosis care

3.3 Factors Driving Growth of the Market and its Impact on Market Forecast

3.3.1 Increasing prevalence of osteoporosis

3.3.2 Rapid urbanization affecting bone health

3.3.3 Increasing prevalence of osteoporosis in post-menopausal women

3.3.4 Increasing healthcare expenditure

3.3.5 Growing geriatric population

3.3.6 Increasing R&D investment in drug discovery and development

3.3.7 Impact analysis of drivers on market forecast

3.4 Factors Hindering Growth of the Market and its Impact on Market Forecast

3.4.1 Side-effects and complications associated with administration of osteoporosis drug

3.4.2 Patent expiration of osteoporosis drug

3.4.3 Limited healthcare reimbursement

3.4.4 Impact analysis of restraints on market forecast

Chapter 4. Drug Approval Process in U.S. and Europe

4.1 Drug approval process in the U.S.

4.2 Drug approval process in the EU

Chapter 5. Global Osteoporosis Drug Market Size and Forecast (2012-2022)

5.1 Global Osteoporosis Drug Market, by Drug Type

5.2 Global Osteoporosis Drug Market, by Region

Chapter 6. Global Osteoporosis Drug Market, by Drug Type

6.1 Bisphosphonates Market

6.1.1 Global bisphosphonates market, by region

6.2 Parathyroid Hormone Therapy Market

6.2.1 Global parathyroid hormone therapy market, by region

6.3 Calcitonin Market

6.3.1 Global calcitonin market, by region

6.4 Selective Estrogen Receptor Modulator (SERM) Market

6.4.1 Global SERM market, by region

6.5 Rank Ligand Inhibitor Market

6.5.1 Global rank ligand inhibitor market, by region

Chapter 7. Global Osteoporosis Drug Market, by Geography

7.1 North America Osteoporosis Drug Market

7.1.1 North America osteoporosis drug market, by drug type

7.1.2 North America osteoporosis drug market, by country

7.2 Europe Osteoporosis Drug Market

7.2.1 Europe osteoporosis drug market, by drug type

7.2.2 Europe osteoporosis drug market, by country

7.3 Asia-Pacific Osteoporosis Drug Market

7.3.1 Asia-Pacific osteoporosis drug market, by drug type

7.3.2 Asia-Pacific osteoporosis drug market, by country

7.4 RoW Osteoporosis Drug Market

7.4.1 RoW osteoporosis drug market, by drug type

Chapter 8. Competitive Analysis

8.1 Porters Five Forces of Competitive Position Analysis

8.1.1 Bargaining power of buyers

8.1.2 Bargaining power of suppliers

8.1.3 Threat of new entrants

8.1.4 Intensity of rivalry

8.1.5 Threat of substitutes

8.2 Competitive Positioning of the Global Osteoporosis Drug Market

8.2.1 Competitive Positioning of Global Osteoporosis Drug Market, by Drug Type

Chapter 9. Company Profiles and Strategic Developments

9.1 Key Company Profiles

9.1.1 Pfizer, Inc.

9.1.1.1 Business overview

9.1.1.2 Product and service offerings

9.1.2 Eli Lily and Company

9.1.2.1 Business overview

9.1.2.2 Product and service offerings

9.1.3 F. Hoffmann La Roche

9.1.3.1 Business overview

9.1.3.2 Product and service offerings

9.1.4 Novartis AG

9.1.4.1 Business overview

9.1.4.2 Product and service offerings

9.1.5 Merck & Co., Inc.

9.1.5.1 Business overview

9.1.5.2 Product and service offerings

9.1.6 Amgen, Inc.

9.1.6.1 Business overview

9.1.6.2 Product and service offerings

9.1.7 Radius Health, Inc.

9.1.7.1 Business overview

9.1.7.2 Product and service offerings

9.1.8 Teva Pharmaceutical Industries Ltd.

9.1.8.1 Business overview

9.1.8.2 Product and service offerings

9.1.9 GlaxoSmithKline plc

9.1.9.1 Business overview

9.1.9.2 Product and service offerings

9.2 Strategic Developments in the Osteoporosis Drug Market

9.2.1 Merger & acquisition

9.2.2 Collaboration/ partnership

9.2.3 Product launch

9.2.4 Others

Chapter 10. Appendix

10.1 List of Abbreviations

 

LIST OF TABLES

TABLE 1: SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION

TABLE 2: GLOBAL OSTEOPOROSIS DRUG MARKET SNAPSHOT

TABLE 3: T-SCORE TABLE

TABLE 4: HEALTHCARE EXPENDITURE AS % OF GDP

TABLE 5: SOME OF THE OSTEOPOROSIS DRUGS IN PIPELINE

TABLE 6: DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 7: RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 8: GLOBAL OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2015)

TABLE 9: GLOBAL OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2016 – 2022)

TABLE 10: GLOBAL OSTEOPOROSIS DRUG MARKET, BY REGION, $M (2012 – 2015)

TABLE 11: GLOBAL OSTEOPOROSIS DRUG MARKET, BY REGION, $M (2016 – 2022)

TABLE 12: GLOBAL BISPHOSPHONATES MARKET, BY REGION, $M (2012 – 2015)

TABLE 13: GLOBAL BISPHOSPHONATES MARKET, BY REGION, $M (2016 – 2022)

TABLE 14: GLOBAL PARATHYROID HORMONE THERAPY MARKET, BY REGION, $M (2012 – 2015)

TABLE 15: GLOBAL PARATHYROID HORMONE THERAPY MARKET, BY REGION, $M (2016 – 2022)

TABLE 16: GLOBAL CALCITONIN MARKET, BY REGION, $M (2012 – 2015)

TABLE 17: GLOBAL CALCITONIN MARKET, BY REGION, $M (2016 – 2022)

TABLE 18: GLOBAL SERM MARKET, BY REGION, $M (2012 – 2015)

TABLE 19: GLOBAL SERM MARKET, BY REGION, $M (2016 – 2022)

TABLE 20: GLOBAL RANK LIGAND INHIBITOR MARKET, BY REGION, $M (2012 – 2015)

TABLE 21: GLOBAL RANK LIGAND INHIBITOR MARKET, BY REGION, $M (2016 – 2022)

TABLE 22: NORTH AMERICA OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2015)

TABLE 23: NORTH AMERICA OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2016 – 2022)

TABLE 24: NORTH AMERICA OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2012 – 2015)

TABLE 25: NORTH AMERICA OSTEOPOROSIS DURG MARKET, BY COUNTRY, $M (2016 – 2022)

TABLE 26: EUROPE OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2015)

TABLE 27: EUROPE OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2016 – 2022)

TABLE 28: EUROPE OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2012 – 2015)

TABLE 29: EUROPE OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2016 – 2022)

TABLE 30: ASIA-PACIFIC OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2015)

TABLE 31: ASIA-PACIFIC OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2016 – 2022)

TABLE 32: ASIA-PACIFIC OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2012 – 2015)

TABLE 33: ASIA-PACIFIC OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2016 – 2022)

TABLE 34: ROW OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2015)

TABLE 35: ROW OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2016 – 2022)

TABLE 36: PFIZER, INC. – KEY FACTS

TABLE 37: ELI LILY AND COMPANY – KEY FACTS

TABLE 38: F. HOFFMANN LA ROCHE – KEY FACTS

TABLE 39: NOVARTIS AG – KEY FACTS

TABLE 40: MERCK & CO., INC. – KEY FACTS

TABLE 41: AMGEN, INC. – KEY FACTS

TABLE 42: RADIUS HEALTH, INC. – KEY FACTS

TABLE 43: TEVA PHARMACEUTICAL INDUSTRIES LTD.– KEY FACTS

TABLE 44: GLAXOSMITHKLINE PLC– KEY FACTS

 

LIST OF FIGURES

FIG 1: RESEARCH SCOPE FOR GLOBAL OSTEOPOROSIS DRUG MARKET

FIG 2: RESEARCH METHODOLOGY FOR GLOBAL OSTEOPOROSIS DRUG MARKET

FIG 3: COMPARISON OF NORMAL BONE AND THE OSTEOPOROTIC BONE

FIG 4: PATHOGENSIS OF OSTEOPOROTIC FRACTURE

FIG 5: SOME OF THE HEALTH PROBLEMS AND MEDICAL PROCEDURES LEADING TO OSTEOPOROSIS

FIG 6: PREVENTIVE MEASURES FOR OSTEOPOROSIS IN WOMEN

FIG 7: SNAPSHOT OF OSTEOPOROSIS

FIG 8: OSTEOPOROSIS FRACTURE WORLDWIDE (1990 AND 2050)

FIG 9: ROLE OF ESTROGEN IN OSTEOPOROSIS

FIG 10: AGING POPULATION AS A PERCENTAGE OF TOTAL POPULATION

FIG 11: GLOBAL OSTEOPOROSIS DRUG MARKET, $M (2012 – 2022)

FIG 12: GLOBAL OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2022)

FIG 13: GLOBAL OSTEOPOROSIS DRUG MARKET SPLIT, BY DRUG TYPE (2015)

FIG 14: GLOBAL OSTEOPOROSIS DRUG MARKET, BY REGION, $M (2012 – 2022)

FIG 15: GLOBAL OSTEOPOROSIS DRUG MARKET SPLIT, BY REGION (2015)

FIG 16: GLOBAL BISPHOSPHONATES MARKET, BY REGION, $M (2012 – 2022)

FIG 17: GLOBAL PARATHYROID HORMONE THERAPY MARKET, BY REGION, $M (2012 – 2022)

FIG 18: GLOBAL CALCITONIN MARKET, BY REGION, $M (2012 – 2022)

FIG 19: GLOBAL SERM MARKET, BY REGION, $M (2012 – 2022)

FIG 20: GLOBAL RANK LIGAND INHIBITOR MARKET, BY REGION, $M (2012 – 2022)

FIG 21: WORLDWIDE MAJOR MARKETS FOR OSTEOPOROSIS DRUG (2022)

FIG 22: NORTH AMERICA OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2022)

FIG 23: NORTH AMERICA OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2012 – 2022)

FIG 24: EUROPE OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2022)

FIG 25: EUROPE OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2012 – 2022)

FIG 26: ASIA-PACIFIC OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2022)

FIG 27: ASIA-PACIFIC OSTEOPOROSIS DRUG MARKET, BY COUNTRY, $M (2012 – 2022)

FIG 28: ROW OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE, $M (2012 – 2022)

FIG 29: PORTER’S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS

FIG 30: COMPETITIVE POSITIONING OF GLOBAL OSTEOPOROSIS DRUG MARKET, BY DRUG TYPE

This research offers actual historical market size for the period 2012 – 2015 and forecast for the period 2016 – 2022 of the global osteoporosis drugs market in the U.S. dollars.

GLOBAL OSTEOPOROSIS DRUGS MARKET

  • By Drug Class
  • By Region

GLOBAL OSTEOPOROSIS DRUGS MARKET, BY DRUG CLASS

  • Bisphosphonates Market
  • Parathyroid Hormone Therapy Market
  • Selective Estrogen Receptor Modulators (SERM’s) Market
  • Rank Ligand Inhibitor Market
  • Calcitonin Market

GLOBAL OSTEOPOROSIS DRUGS MARKET, BY GEOGRAPHY

  • North America Osteoporosis Drugs Market
    • By Drug Class
    • By Country (U.S. and Rest of North America)
  • Europe Osteoporosis Drugs Market
    • By Drug Class
    • By Country (Germany, France, U.K., and Rest of the Europe)
  • Asia-Pacific Osteoporosis Drugs Market
    • By Drug Class
    • By Country (India, China, Japan and Rest of Asia-Pacific)
  • Rest of the World (RoW) Osteoporosis Drugs Market
    • By Drug Class

Please fill the form to get the sample pages.

  

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

$5100
Group License

Group License authorizes access of the publication upto 5 users.

$6100
Site License

Site License authorizes access of the publication to all the employees of the organization at a single geographic location.

$7100
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

$9100
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment